Compare CRWS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | BLRX |
|---|---|---|
| Founded | 1957 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 12.6M |
| IPO Year | 1994 | 2010 |
| Metric | CRWS | BLRX |
|---|---|---|
| Price | $2.69 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 26.7K | 15.2K |
| Earning Date | 02-11-2026 | 05-26-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $2.15 |
| 52 Week High | $3.38 | $7.77 |
| Indicator | CRWS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 34.48 |
| Support Level | $2.40 | N/A |
| Resistance Level | $2.94 | $3.93 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 63.53 | 8.33 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.